BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37623025)

  • 21. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.
    Hallet J; Law CH; Cukier M; Saskin R; Liu N; Singh S
    Cancer; 2015 Feb; 121(4):589-97. PubMed ID: 25312765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?
    Stiefel R; Lehmann K; Winder T; Siebenhüner AR
    BMC Cancer; 2023 Feb; 23(1):148. PubMed ID: 36782152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinicopathological characteristics and prognosis analysis of colorectal neuroendocrine neoplasms based on the data from domestic six medical centers].
    Zhang Y; Peng X; Jin K; Wang W; Feng X; Zeng Y; Chen M; Yu X; Chen Y; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1235-1240. PubMed ID: 27928792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant
    Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S
    J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.
    Boudreaux JP; Klimstra DS; Hassan MM; Woltering EA; Jensen RT; Goldsmith SJ; Nutting C; Bushnell DL; Caplin ME; Yao JC;
    Pancreas; 2010 Aug; 39(6):753-66. PubMed ID: 20664473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
    Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
    World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neuroendocrine tumors of the small bowels are on the rise: early tumors and their management].
    Scherübl H; Schwertner C; Steinberg J; Stölzel U; Pohl J; Dralle H; Klöppel G
    Z Gastroenterol; 2010 Mar; 48(3):406-13. PubMed ID: 20183784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Simultaneous Resection of Small Bowel Neuroendocrine Tumors with Synchronous Liver Metastases.
    Addeo P; Bertin JB; Imperiale A; Averous G; Terrone A; Goichot B; Bachellier P
    World J Surg; 2020 Jul; 44(7):2377-2384. PubMed ID: 32179974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours.
    Almeamar H; Cullen L; Murphy DJ; Crowley RK; Toumpanakis C; Welin S; O'Shea D; O'Toole D
    J Neuroendocrinol; 2022 Jun; 34(6):e13138. PubMed ID: 35485450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between surveillance imaging and survival outcomes in small bowel neuroendocrine tumors.
    Watanabe A; Mckendry G; Yip L; Loree JM; Stuart HC
    J Surg Oncol; 2023 Mar; 127(4):578-586. PubMed ID: 36537012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.
    Lenotti E; Alberti A; Spada F; Amoroso V; Maisonneuve P; Grisanti S; Baggi A; Bianchi S; Fazio N; Berruti A
    Front Endocrinol (Lausanne); 2021; 12():669484. PubMed ID: 33986731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand.
    McGuinness MJ; Woodhouse B; Harmston C; Parker K; Kramer N; Findlay M; Print C; Merrie A; Lawrence B
    ANZ J Surg; 2022 Jul; 92(7-8):1748-1753. PubMed ID: 35762209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival.
    Daskalakis K; Karakatsanis A; Hessman O; Stuart HC; Welin S; Tiensuu Janson E; Öberg K; Hellman P; Norlén O; Stålberg P
    JAMA Oncol; 2018 Feb; 4(2):183-189. PubMed ID: 29049611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extent of Lymph Node Dissection for Small Bowel Neuroendocrine Tumors.
    Hallet J; Law C;
    World J Surg; 2021 Jan; 45(1):197-202. PubMed ID: 32737557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
    Özaslan E; Karaca H; Koca S; Sevinç A; Hacioğlu B; Özkan M; Özçelik M; Duran AO; Hacibekiroğlu İ; Yildiz Y; Tanriverdi Ö; Menekşe S; Aksoy A; Bozkurt O; Urvay S; Uysal M; Demir H; Çiltaş A; Dane F
    Anticancer Drugs; 2017 Feb; 28(2):222-229. PubMed ID: 27768606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis.
    Katona BW; Roccaro GA; Soulen MC; Yang YX; Bennett BJ; Riff BP; Glynn RA; Wild D; Nicolas GP; Pryma DA; Teitelbaum UR; Metz DC
    Pancreas; 2017 Oct; 46(9):1121-1126. PubMed ID: 28902781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Evolving Landscape of Neuroendocrine Tumors.
    Russo A; Gangi A
    Surg Oncol Clin N Am; 2023 Jan; 32(1):185-198. PubMed ID: 36410917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.